Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-22
2011-12-06
Murray, Jeffrey (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08071607
ABSTRACT:
The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2aor Mnk2b) and/or variants thereof.
REFERENCES:
patent: 408945 (1966-03-01), None
patent: WO2004/037159 (2004-05-01), None
patent: WO2004/106340 (2004-12-01), None
Wolff et. al., “Burger's Medicinal Chemistry and Drug Discovery,” 5th Ed. Part 1, pp. 975-977 (1995).
http://www.medterms.com/script/main/art.asp?articlekey=12063, last accessed on Aug. 24, 2010.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Banker, et. al., Modern Pharmaceuticals, p. 596.
Cheng, et al., “Potential Purine Antagonists, VI.”, Journal of Organic Chemistry, American Chemical Society, Easton, US, vol. 21, Nov. 1, 1956, pp. 1240-1256.
Young, et al., “Purine Derivatives as Competitive Inhibitors of Human Erythrocyte Membrane Phosphatidylinositol 4-Kinase”, Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 33, No. 8 Aug. 1, 1990, pp. 2073-2080.
Peat, et al., “Novel Pyrazolopyrimidine Derivatives as GSK-3 Inhibitors.” Bioorganic & Medicinal Chemistry Letters. May 3, 2004, vol. 14, No. 9, pp. 2121-2125.
Traxler et al., “Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)Pyrazolo3,4-Dpyrimidines”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 40, No. 22, 1997, pp. 3601-3616.
Aicher Babette
Coulter Thomas Stephen
Jaekel Stefan
Murfin Stephen
Reuter Tanja
Boehringer Ingelheim International GmbH
Lando & Anastasi LLP
Murray Jeffrey
LandOfFree
Mnk1 or Mnk2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mnk1 or Mnk2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mnk1 or Mnk2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293391